WCLC 2016: Fruquintinib Phase II Study in Advanced NSCLC

A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer  (NCT02590965)

Shun Lu¹, Jianhua Chang², XiaoQing Liu³, Jianhua Shi⁴, You Lu⁵, Wei Li⁶, Jinji Yang⁷, Jianying Zhou⁸, Jie Wang⁹, Lei Yang¹⁰, Zhiwei Chen¹, Xiangdong Zhou¹¹, Zhe Liu¹², Ye Hua¹³, Weiguo Su¹³

¹ Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/China; ² Fudan University Shanghai Cancer Center, Shanghai/China; ³ 307 Hospital of the Academy of Military Medical Sciences, Beijing/China; ⁴ Linyi Tumor Hospital, Linyi/China; ⁵ West China Hospital, Chengdu/China ; ⁶ The First Hospital of Jilin University, Changchun/China; ⁷ Guangdong General Hospital, Guangzhou/China; ⁸ The First Affiliated Hospital, Hangzhou/China; ⁹ Beijing Cancer Hospital and Institute, Beijing/China; ¹⁰ Nantong Tumor Hospital, Nantong/China; ¹¹ Xi’nan Hospital, Chongqing/China; ¹² Beijing Chest Hospital, Beijing/China; ¹³ Hutchison MediPharma Limited, Shanghai/China